Daniel R Ganger

Northwestern Memorial Hospital, Digestive Health Foundation

7/1/19 → 6/30/20

Project: Research project

Prot# M16-135: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

AbbVie Inc.

9/8/17 → 9/7/20

Project: Research project

Prot# MNK19013058: A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1

International HealthCare, LLC, Mallinckrodt Hospital Products Inc.

6/15/16 → 6/15/21

Project: Research project

Acute Liver Failure Study Group 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure

University of Texas Southwestern Medical Center at Dallas, National Institute of Diabetes, Digestive and Kidney Diseases

2/19/16 → 8/31/20

Project: Research project

Breath Tests

Acute Liver Failure

Time Management

Registries

Clinical Trials

A Multi-Center Group to Study Acute Liver Failure

University of Texas Southwestern Medical Center at Dallas, National Institute of Diabetes, Digestive and Kidney Diseases

9/16/15 → 8/31/20

Project: Research project

Acute Liver Failure

Hematologic Diseases

Liver

Sepsis

Viruses

Prot# 017-00: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial

University of California, San Francisco, National Institute on Aging

3/18/13 → 3/31/21

Project: Research project

Finished

Frailty and Functional Status in Older Liver Transplant Patients

Ganger, D. R. & Ladner, D. P.

9/15/18 → 8/31/19

Project: Research project

Transplants

Liver

Mortality

Decision Support Techniques

Liver Transplantation

A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) -- A Multi-Center Group to Study Acute Liver Failure

University of Texas Southwestern Medical School, National Institute of Diabetes, Digestive and Kidney Diseases

9/18/15 → 8/31/19

Project: Research project

Acute Liver Failure

Safety

Liver

Wounds and Injuries

Therapeutics

Prot #MK-3682-012-01: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection.

8/5/15 → 8/5/18

Project: Research project

Prot # 052-00: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease

Quintiles, Inc., Takeda Development Center Americas, Inc.

3/4/14 → 3/4/17

Project: Research project

Prot # ROF-NASH_205: A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis

Ganger, D. R., Green, R., Kulik, L. M. & Rinella, M. E.

2/11/14 → 2/11/17

Project: Research project

Prot # OCR002-HE209: Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopa

Valeant Pharmaceuticals North America LLC, Salix Pharmaceuticals, Inc.

Ocera Therapeutics, Inc

11/8/13 → 11/8/18

Project: Research project

RFHE4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment and Overt Hepatic Encephalopathy

Ganger, D. R. & Levitsky, J.

3/12/13 → 12/31/15

Project: Research project

Protocol # 038-00: A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 when Administered Concomitantly with Peginterferon alfa-2b and Rabavirin in Treatment Naive Subjects wi

1/24/13 → 1/24/16

Project: Research project

Prot # GS-US-337-0109: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV I

PRA Health Sciences, Gilead Sciences, Inc.

1/4/13 → 1/4/17

Project: Research project

Prot # M11-646: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered with Ribavarin (RBV) in Treatment-Naive Adults with Genotype 1 Chronic He

AbbVie Inc.

11/29/12 → 11/29/15

Project: Research project

Prot # GS-US-337-0102: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavarin for 12 and 24 Weeks in Treatment-Naive Subjects with Chronic Genotype 1 HCV Infecti

PRA Health Sciences, Gilead Sciences, Inc.

10/5/12 → 10/5/15

Project: Research project

Adduct Dipstick for Diagnosis of Acetaminophen Toxicity

Arkansas Children's Hospital Research Institute, National Institute of Diabetes, Digestive and Kidney Diseases

7/1/12 → 6/30/15

Project: Research project

Acetaminophen

Acute Liver Failure

Research

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)

High Pressure Liquid Chromatography

Prot # 003-23: A Phase II Randomized, Partially Blinded, Pilot Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Treatment-Naive (TN) Patients with Chronic Genotype 1 (GT 1) Hepatitis C Virus Infection" MK-5172-03

6/1/12 → 6/1/13

Project: Research project

Prot # AI444052: A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C

Bristol-Myers Squibb Company

5/9/12 → 5/9/15

Project: Research project

Prot# GX-US-174-0172: Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Trans

PRA Health Sciences, Gilead Sciences, Inc.

3/19/12 → 3/19/18

Project: Research project

Prot# VX11-222-106: A Multicenter, Randomized, Double-blind, Placebo- Controlled, Phase 2b Study to Compare the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, Ribavirin) to Triple Therapy (with VX-222-Placebo) in Subje

Parexel, Vertex Pharmaceuticals Incorporated

3/15/12 → 3/15/16

Project: Research project

Prot# VX11-950-116: An Open-Label, Phase 4 study of Telaprevir, Peginterferon Alfa-2a(Pegasys), and Ribavirin(Copegus) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not

Parexel, Vertex Pharmaceuticals Incorporated

3/8/12 → 3/8/16

Project: Research project

Prot # VX11-950-114: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype

Parexel, Vertex Pharmaceuticals Incorporated

3/8/12 → 3/8/16

Project: Research project

Protocol TMC435HPC2002:An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior